Laboratory Tests for Patients With Ileal Pouch–Anal Anastomosis: Clinical Utility in Predicting, Diagnosing, and Monitoring Pouch Disorders

Navaneethan, Udayakumar; Shen, Bo
October 2009
American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2606
Academic Journal
Restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC-associated dysplasia, and for the majority of patients with familial adenomatous polyposis. Pouchitis and other complications of IPAA are common. There are scant data on laboratory markers for the evaluation and diagnosis of pouch disorders. The presence of immunogenotypic markers such as genetic polymorphisms of interleukin-1 (IL-1) receptor antagonist, NOD2/CARD15, Toll-like receptor, and tumor necrosis factor-α has been reported to be associated with pouchitis. Immunophenotypic/serologic markers such as perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 have been investigated as possible markers for predicting and diagnosing pouchitis. Fecal markers including lactoferrin and calprotectin seem to be useful in distinguishing inflammatory from noninflammatory pouch disorders. In our practice, we have encountered a large number of pouch patients with Clostridium difficile infection. Laboratory evaluation provides information on the etiology and pathogenesis of pouchitis, and it also helps practicing clinicians with accurate diagnosis, differential diagnosis, disease stratification, and management of ileal pouch disorders.


Related Articles

  • Clostridium difficile Pouchitis after Proctocolectomy with Ileal Pouch--Anal Anastomosis. Pricolo, Victor E.; Chao, Steven; Gregorian, Armen // American Surgeon;Nov2011, Vol. 77 Issue 11, pE214 

    The article describes the case of an 18-year old male patient with refractory ulcerative colitis who developed Clostridium difficile enteritis and pouchitis in the immediate postoperative course after restorative proctocolectomy and ileal pouch-anal anastomosis. The patient underwent a computed...

  • The Risk of Cancer and Dysplasia among Ulcerative Colitis Patients with Primary Sclerosing Cholangitis. Marchesa, Pierenrico; Lashner, Bret A.; Lavery, Ian C.; Milsom, Jeffrey; Hull, Tracy L.; Strong, Scott A.; Church, James M.; Navarro, Georgia; Fazio, Victor W. // American Journal of Gastroenterology;Aug1997, Vol. 92 Issue 8, p1285 

    Background: Ulcerative colitis (UC) patients with primary sclerosing cholangitis (PSC) may have an increased risk for colonic dysplasia or cancer. They also may have higher levels of carcinogenic secondary bile acids and, thus, be more likely to develop cancer in the right side of the colon,...

  • Clinical features and management of pouchitis in Japanese ulcerative colitis patients. Uchino, Motoi; Ikeuchi, Hiroki; Matsuoka, Hiroki; Bando, Toshihiro; Takesue, Yoshio; Tomita, Naohiro // Surgery Today;Sep2013, Vol. 43 Issue 9, p1049 

    Purpose: Pouchitis frequently occurs after restorative proctocolectomy for ulcerative colitis. This study evaluated the incidence and treatment of pouchitis in Japanese ulcerative colitis patients. Method: This study reviewed the clinical data from 772 patients with pouch surgery between January...

  • Expression of costimulatory molecule CD80 in colonic dysplasia in ulcerative colitis: an immunosurveillance mechanism against colorectal cancer? Scarpa, Marco; Behboo, Roubik; Angriman, Imerio; Cecchetto, Attilio; D’Incà, Renata; Termini, Barbara; Barollo, Michela; Ruffolo, Cesare; Polese, Lino; Sturniolo, Giacomo Carlo; D’Amico, Davide Francesco // International Journal of Colorectal Disease;Dec2006, Vol. 21 Issue 8, p776 

    Ulcerative colitis is an established risk factor for colorectal cancer but dysplasia reports are much more frequent than invasive neoplasm diagnosis. The effective activation of T lymphocytes that provide antitumor surveillance requires the presence of costimulation molecules such as CD80 and...

  • Surveillance for dysplasia in patients with ileal pouch-anal anastomosis for ulcerative colitis: an interim analysis. Meléndez Hernández, Jorge; Jiménez-Huyke, Carlos; Rosado, Kathia; González-Keelan, Carmen; Lojo, Juan; Torres, Esther; Hernández, Jorge D Meléndez; Jiménez-Huyke, Carlos; González-Keelan, Carmen; Lojo, Juan J; Torres, Esther A // Digestive Diseases & Sciences;Aug2010, Vol. 55 Issue 8, p2332 

    Background: The risk of developing cancer in the ileal pouch of patients with surgery for ulcerative colitis has not been defined. Dysplasia in the pouch is quite rare. Although some suggest pouch surveillance based on previous histological assessments, there are no guidelines for...

  • Long-Term Followup of Patients with Active J-Reservoirs after Restorative Proctocolectomy for Ulcerative Colitis with regard to Reservoir Function, Mucosal Changes, and Quality of Life. Røkke, Ola; Iversen, Knut; Olsen, Torill; Ristesund, Sølvi-May; Eide, Geir Egil; Turowski, Gitta Erika // ISRN Gastroenterology;2011, Special section p1 

    Objective. Study the functional results and mucosal changes in the ileal pouch after restorative proctocolectomy with J-reservoir for ulcerative colitis. Material and Methods. Followup study of 125 patients with J-reservoir with one disease-specific- and one general (SF-36) quality of...

  • FUNCTIONAL OUTCOME AND QUALITY OF LIFE AFTER RESTORATIVE PROCTOCOLECTOMY AND ILEAL POUCH-ANAL ANASTOMOSIS. Gj., Jota; Z., Karadžov; M., Panovski; N., Joksimović; A., Kartalov; R., Gelevski; V., Joksimovic; V., Serafimoski // Contributions of Macedonian Academy of Sciences & Arts;2011, Vol. 32 Issue 2, p221 

    Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice for patients with medically refractory ulcerative colitis, ulcerative colitis with dysplasia or cancer, or familial adenomatous polyposis (FAP). The aim of this study is to report our 6-year...

  • Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. Avdagić1, Nesina; Babić1, Nermina; Šeremet2, Mensura; Delić-Šarac3, Marina; Drače3, Zahida; Denjalić4, Amir; Nakaš-Ićindić1, Emina // Medicinski Glasnik;Aug2013, Vol. 10 Issue 2, p211 

    Aim To investigate an influence of the concentration of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) in serum on the activity of inflammatory bowel disease (IBD). Methods The IBD patients of both genders (n=60) were divided in two equal groups, ulcerative colitis (UC) and...

  • C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. Iwasa, Ryota; Yamada, Akihiro; Sono, Koji; Furukawa, Ryuichi; Takeuchi, Ken; Suzuki, Yasuo // BMC Gastroenterology;Aug2015, Vol. 15 Issue 1, p1 

    Background: Poor response to anti-tumour necrosis factor biologicals like infliximab (IFX) is observed in patients with ulcerative colitis (UC), which may lead to prolonged morbidity and waste of medical resources. We aimed to look for potential biomarkers of response to IFX in patients with UC...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics